MentionFox
Home › Executive changes › Heron Therapeutics, Inc. /De/
Leadership changes · SEC Form 8-K, Item 5.02

Heron Therapeutics, Inc. /De/ executive changes

Every leadership change Heron Therapeutics, Inc. /De/ reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings1
Latest filing2026-04-06

Heron Therapeutics, Inc. /De/ filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-04-06. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-04-06 · 8-K

Reported

For the purpose of determining the number of shares subject to acceleration of vesting described in clause (ii) above for any outstanding performance-based equity awards that may be granted after the Collard Amendment Effective Date that have a designated "target" and "maximum" vesting level, the performance vesting conditions will generally be deemed satisfied at the greater of (A) the applicable level of performance attained through the date of such termination, or (B) the target performance vesting level (the "Performance-Based Vesting Criteria").
Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Heron Therapeutics, Inc. /De/, with the record behind each one.

Find candidates like senior executive at Heron Therapeutics, Inc. /De/
Selling to Heron Therapeutics, Inc. /De/?

New leaders review vendors and budgets in their first months. Get an alert the next time Heron Therapeutics, Inc. /De/ is in the news or changes leadership.

Get an alert when Heron Therapeutics, Inc. /De/ changes leadership

Tools for this story

Each opens in a new tab, filled in for Heron Therapeutics, Inc. /De/. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/heron-therapeutics-inc-de
Last updated 2026-09-27
Primary record: SEC filing
Heron Therapeutics, Inc. /De/ (HRTX) executive changes: 1 leadership filing. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/heron-therapeutics-inc-de